Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FD1BK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,143
Award facts
- Contract value 100% obligated
- $15,143.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $15,143.20 to DMS Pharmaceutical Group Inc. for the supply of Nucala 100 mg/ml auto-injector medication, with an ultimate completion date of September 12, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order falls under the company's existing Indefinite Delivery Contract with the DLA valued at approximately $500 million through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide.
Nucala (mepolizumab) is a biologic medication used to treat severe eosinophilic asthma and other eosinophilic conditions, and the auto-injector formulation enhances patient accessibility and ease of administration for military and federal healthcare beneficiaries. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently delivering branded and generic prescription drugs, biologics, and specialty medications to military health facilities. The company's robust contract portfolio with the DLA demonstrates its capability to manage complex pharmaceutical procurement requirements and ensure reliable distribution of critical medications to support Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DB25FD1BK?
SPE2DB25FD1BK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 11, 2025.
How much is contract SPE2DB25FD1BK worth?
The government has obligated $15,143 on SPE2DB25FD1BK.
Is contract SPE2DB25FD1BK an order under another contract?
Yes. SPE2DB25FD1BK is a delivery order under SPE2DB20D9226, an indefinite delivery contract.
Was contract SPE2DB25FD1BK competed?
The extent of competition for SPE2DB25FD1BK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award